These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27037661)

  • 1. Rebound pustular psoriasis after brodalumab discontinuation.
    Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
    Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
    Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
    J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab: A Review of Safety.
    Rusta-Sallehy S; Gooderham M; Papp K
    Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe myalgia associated with brodalumab treatment in a patient with psoriasis.
    Ichiyama S; Matano Y; Hoashi T; Kanda N; Nagayama H; Saeki H
    J Dermatol; 2018 Dec; 45(12):e327-e328. PubMed ID: 29782052
    [No Abstract]   [Full Text] [Related]  

  • 5. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
    Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
    Yamasaki K; Nakagawa H; Kubo Y; Ootaki K;
    Br J Dermatol; 2017 Mar; 176(3):741-751. PubMed ID: 27106510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
    Galluzzo M; Talamonti M; D'adamio S; Bianchi L
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
    Schmidt C
    Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.
    Fairhurst DA; Sheehan-Dare R
    Clin Exp Dermatol; 2009 Apr; 34(3):421-2. PubMed ID: 19309375
    [No Abstract]   [Full Text] [Related]  

  • 10. What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
    Hashim PW; Chen T; Lebwohl MG; Marangell LB; Kircik LH
    J Drugs Dermatol; 2018 Aug; 17(8):s29-s34. PubMed ID: 30124737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of skin infection during psoriasis treatment with brodalumab.
    Kobayashi M; Nagata M; Oaku S; Kanda N; Tada Y; Aozasa N
    J Dermatol; 2018 Mar; 45(3):e51-e52. PubMed ID: 29083051
    [No Abstract]   [Full Text] [Related]  

  • 15. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
    Nijsten T; Spuls PI
    Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
    [No Abstract]   [Full Text] [Related]  

  • 16. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.